Effect of oral Magnesium in diabetic neuropathy
- Conditions
- Peripheral polyneuropathy in type 2 diabetes.Type 2 diabetes mellitus with diabetic polyneuropathyE11.42
- Registration Number
- IRCT20230522058258N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Men and women between the ages of 20 and 85
Having type 2 diabetes (whose type 2 diabetes has already been proven by tests of FBS > 126 and HbA1c > 6.5 and they are being treated with oral antidiabetic drugs or insulin)
Having the symptoms of distal peripheral polyneuropathy: feeling pain and excessive sensitivity or reduced sensation or feeling of burning, tingling and murmur in the hands or feet of the patient
Suffering from other neuropathies other than diabetic neuropathy
Neuromuscular diseases (such as myasthenia gravis)
Magnesium level above 2.1
History of magnesium consumption in the last 3 months
A history of persistent diarrhea and vomiting
History of diuretic use with a dose of more than 40 mg
History of thyroid diseases or levothyroxine use
History of heart block or use of calcium channel blockers
Having chronic kidney disease (GFR<60)
Taking antidepressants, anticonvulsants, or analgesics
Pregnancy and breastfeeding
History of any malignancy
History of amputation or active diabetic foot ulcer
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method